IRX-2, a Novel Immunotherapeutic, Enhances Functions of Human Dendritic Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Schilling, Bastian ^a   Harasymczuk, Malgorzata ^a   Schuler, Patrick ^a   Egan, James ^b   Ferrone, Soldano ^a   Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b IRX Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CD40 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GLYCOPROTEIN P 15095; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRX 2; LATENT MEMBRANE PROTEIN 2; SECONDARY LYMPHOID TISSUE CHEMOKINE; TAPASIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELL ASSAY; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; MALE; MONOCYTE; PHENOTYPE; TUMOR IMMUNITY; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; PHAGOCYTOSIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84873589785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047234     Document Type: Article

References (41)

1. Banchereau J, Steinman RM, (1998) Dendritic cells and the control of immunity. Nature 392: 245-252.
2. Pinzon-Charry A, Maxwell T, Lopez JA, (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83: 451-461.
3. Chaux P, Moutet M, Faivre J, Martin F, Martin M, (1996) Inflammatory cells infiltrating human colorectal carcinomas express HLA class II but not B7-1 and B7-2 costimulatory molecules of the T-cell activation. Lab Invest 74: 975-983.
4. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP, (1997) Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 3: 483-490.
5. Young MR, Wright MA, Lozano Y, Prechel MM, Benefield J, et al. (1997) Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer 74: 69-74.
6. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, et al. (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766.
7. Procko E, Gaudet R, (2009) Antigen processing and presentation: TAPping into ABC transporters. Curr Opin Immunol 21: 84-91.
8. Amigorena S, Savina A, (2010) Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 22: 109-117.
9. Lopez-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang X, et al. (2009) Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother 32: 465-473.
10. Whiteside TL, Stanson J, Shurin MR, Ferrone S, (2004) Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol 173: 1526-1534.
11. Kirkwood JM, Lee S, Moschos SJ, Albertini MR, Michalak JC, et al. (2009) Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 15: 1443-1451.
12. Rapidis AD, Wolf GT, (2009) Immunotherapy of head and neck cancer: current and future considerations. J Oncol 2009: 346345.
13. Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, et al. (2012) Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother 61: 771-782.
14. Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, et al. (2011) Novel neoadjuvant immunotherapy regimen. Safety and survival in head and neck squamous cell cancer. Head and Neck 33: 1666-1674.
15. Egan JE, Quadrini KJ, Santiago-Schwarz F, Hadden JW, Brandwein HJ, et al. (2007) IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro. J Immunother 30: 624-633.
16. Whiteside TL, Butterfield LH, Naylor PH, Egan JE, Hadden JW, et al. (2012) A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma. Cancer Immunol Immunother 61: 783-788.
17. Reis e Sousa C, (2006) Dendritic cells in a mature age. Nat Rev Immunol 6: 476-483.
18. Frasca L, Nasso M, Spensieri F, Fedele G, Palazzo R, et al. (2008) IFN-gamma arms human dendritic cells to perform multiple effector functions. J Immunol 180: 1471-1481.
19. Butterfield LH, Gooding W, Whiteside TL, (2008) Development of a potency assay for human dendritic cells: IL-12p70 production. J Immunother 31: 89-100.
20. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH, (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192: 1213-1222.
21. Muthuswamy R, Mueller-Berghaus J, Haberkorn U, Reinhart TA, Schadendorf D, et al. (2010) PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. Blood 116: 1454-1459.
22. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, et al. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188: 373-386.
23. Hoffmann TK, Meidenbauer N, Muller-Berghaus J, Storkus WJ, Whiteside TL, (2001) Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 24: 162-171.
24. Ma DY, Clark EA, (2009) The role of CD40 and CD154/CD40L in dendritic cells. Semin Immunol 21: 265-272.
25. Sadhu C, Ting HJ, Lipsky B, Hensley K, Garcia-Martinez LF, et al. (2007) CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity. J Leukoc Biol 81: 1395-1403.
26. Langlade-Demoyen P, Levraud JP, Kourilsky P, Abastado JP, (1994) Primary cytotoxic T lymphocyte induction using peptide-stripped autologous cells. Int Immunol 6: 1759-1766.
27. Kalinski P, (2009) Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4. Curr Opin Investig Drugs 10: 526-535.
28. Agnello D, Lankford CS, Bream J, Morinobu A, Gadina M, et al. (2003) Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol 23: 147-161.
29. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, et al. (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29: 330-336.
30. Ahmadi M, Emery DC, Morgan DJ, (2008) Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res 68: 7520-7529.
31. Schilling B, Harasymczuk M, Schuler P, Egan JE, Whiteside TL, (2012) IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model. J Mol Med 90: 139-147.
32. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, et al. (2003) Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 62: 385-393.
33. Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, et al. (2005) Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66: 185-194.
34. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, et al. (2005) A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Meth 299: 139-151.
35. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, et al. (1989) Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma 8: 85-95.
36. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, et al. (2000) Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 165: 5938-5944.
37. Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, et al. (2007) Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 67: 10538-10545.
38. Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, et al. (1989) Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 49: 5167-5175.
39. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, et al. (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27: 3135-3142.
40. Poon IK, Parish CR, Hulett MD, (2010) Histidine-rich glycoprotein functions cooperatively with cell surface heparan sulfate on phagocytes to promote necrotic cell uptake. J Leukoc Biol 88: 559-569.
41. Kim GG, Donnenberg VS, Donnenberg AD, Gooding W, Whiteside TL, (2007) A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay. J Immunol Meth 325: 51-66.